On July 28, 2021 Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology,reported that an independent study of 166 women in Hungary showed that LuViva detected 20% more cervical precancer and cancer than the HPV test (Press release, Guided Therapeutics, JUL 28, 2021, View Source [SID1234585312]). Specifically, LuViva had a very high sensitivity of 94%, detecting disease in 48 of 51 women with biopsy results of precancer or cancer, compared with 40 detected by HPV for the same group of 51 women. In addition, the confidence that a negative LuViva result truly indicated no significant disease (negative predictive value) was 90% for LuViva and 81% for HPV. The confidence that a positive test result truly indicated presence of disease (positive predictive value) was about the same for both LuViva (35%) and HPV (37%). According to new U.S. guidelines, women with this high a likelihood of cervical disease or higher need to either have tissue removed for a definitive diagnosis or consider immediate treatment. In contrast to HPV testing, LuViva does not require a costly and time-consuming lab infrastructure and provides results immediately as opposed to the delay of several days for lab tests such as the Pap or HPV. The study was conducted by a team led by Prof. Dr. Zoltan Hernadi at the Department of Obstetrics and Gynecology at the University of Debrecen, Hungary.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As published in the Hungarian medical journal Orvosi Hetilap, Prof. Hernadi and his team concluded that the LuViva test "is another opportunity to improve the quality of our Hungarian cervical screening system. Highlights of the test are high sensitivity and negative predictive value." LuViva has earned the CE Mark and is working with its European manufacturing and distribution partner Newmars Technologies to launch the product this year in Central and Eastern Europe and next year in Russia.
According to the World Health Organization, cervical cancer is ranked as the fourth most common type of cancer in women worldwide, with approximately 700,000 cases reported annually. Because cervical cancer often is detected too late, it is one of the leading causes of cancer-related female death in developing countries, with 311,000 women lost each year.